Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$2.45
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $112.3M · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$764M
P/E
8.4x
↓EV/EBITDA
3.8x
↓ROE
12.6%
↑Gross Margin
86.3%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+13.3%
FCF CAGR
+41.4%
FCF margin
52.5%
FCF / Net income
1.23x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $214.0M · net income $91.3M · FCF $112.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $214.0M | $214.0M | $236.9M | $259.3M | $147.3M |
| Net Income | $91.3M | $91.3M | $78.6M | $105.0M | $30.0M |
| EBITDA | $113.9M | $113.9M | $105.7M | $136.8M | $45.9M |
| EPS | — | — | 0.25 | 0.34 | 0.10 |
| Gross Margin | 86.3% | 86.3% | 86.2% | 84.5% | 78.9% |
| Operating Margin | 51.3% | 51.3% | 53.0% | 55.2% | 33.0% |
| Net Margin | 42.7% | 42.7% | 33.2% | 40.5% | 20.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 18.40 | 18.40 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $112.3M | $112.3M | $78.0M | $144.8M | $39.8M |
| Returns | |||||
| ROE | 12.6% | 12.6% | 10.7% | 13.7% | 4.2% |
| Valuation | |||||
| P/E | 8.45 | 8.45 | 9.84 | 5.34 | 12.50 |
| EV/EBITDA | 3.84 | 3.84 | 4.74 | 2.19 | 4.58 |
| P/B | 1.06 | 1.06 | 1.06 | 0.73 | 0.53 |
| Growth & Yield | |||||
| Revenue Growth | -9.7% | -9.7% | -8.6% | 76.0% | — |
| EPS Growth | — | — | -25.2% | 251.0% | — |
| Dividend Yield | 2.8% | 2.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+4.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.25 → n/d
Residual
+2.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.